



IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): ~~4-Substituted~~ A 4-substituted aryl-5-hydroxyisoquinolinone ~~derivatives~~ compound represented by a ~~general~~ formula (1)




[[[[]]]]wherein ring Ar denotes a phenyl group, naphthyl group, 5- or 6-membered aromatic heterocycle [[and]] or its condensed ring, R1 denotes a hydrogen atom or halogen atom, R2 denotes a hydrogen atom, halogen atom, hydroxy group, lower alkyl group which may be substituted with halogen atom, cycloalkyl group which may be substituted with halogen atom, lower alkoxy group which may be substituted with halogen atom, aralkyloxy group which may have substituents, nitro group, amino group which may have substituents, aralkyl group which may have substituents, phenyl group which may have substituents, naphthyl group which may have substituents, or 5-or 6-membered heterocycle which may have substituents and its condensed ring, A denotes a C1~C4 alkylene or C2~C4 alkenylene, R3 denotes a hydrogen atom, lower alkyl group which may be substituted with halogen atom, or ~~general~~ formula (2)



[[([[]])]wherein Q1 denotes a C1~C4 alkylene, and R5 denotes a hydroxy group, lower alkoxy group which may be substituted with halogen atom, amino group which may have substituents, lower alkoxy carbonyl group or carboxy group[[[]]], R4 denotes a lower alkyl group which may be substituted with halogen atom, cycloalkyl group which may have substituents, phenyl group which may have substituents, naphthyl group which may have substituents, or 5- or 6-membered heterocycle which may have substituents and its condensed ring, ~~general~~ formula (3)




wherein Q2 denotes a C1~C4 alkylene, and R6 denotes a hydroxy group, lower alkoxy group which may be substituted with halogen atom, lower alkoxy carbonyl group, carboxy group, cycloalkyl group which may have substituents, cycloalkenyl group which may have substituents, phenyl group which may have substituents, naphthyl group which may have substituents, or 5- or 6-membered heterocycle which may have substituents and its condensed ring, or general formula (4)



wherein R7 and R8 denote identically or differently hydrogen atoms, lower alkyl groups which may be substituted with halogen atom, aralkyl groups which may have substituents, or R7 and R8 are bound together to form a 5- or 6-membered heterocycle which may have substituents and its condensed ring, or R3 with R4 are bound together to form a 5- or 6-membered heterocycle which may have substituents and its condensed ring, and their or a pharmacologically acceptable addition salt thereof.

Claim 2 (Currently Amended): ~~4-Substituted~~ The 4-substituted aryl-5-hydroxyisoquinolinone ~~derivatives~~ compound of Claim 1, represented by a ~~general~~ formula (1a)



wherein ring Ar denotes a phenyl group, naphthyl group, 5- or 6-membered aromatic heterocycle or its condensed ring, R1 denotes a hydrogen atom or halogen atom, R2a denotes a hydrogen atom, halogen atom, hydroxy group, lower alkyl group which


may be substituted with halogen atom, lower alkoxy group which may be substituted with halogen atom, nitro group, or amino group which may have substituents, A denotes a C1~C4 alkylene or C2~C4 alkenylene, R3 denotes a hydrogen atom, lower alkyl group which may be substituted with halogen atom, or ~~general~~ formula (2)



wherein Q1 denotes a C1~C4 alkylene, and R5 denotes a hydroxy group, lower alkoxy group which may be substituted with halogen atom, amino group which may have substituents, lower alkoxy carbonyl group or carboxy group, R4 denotes a lower alkyl group which may be substituted with halogen atom, cycloalkyl group which may have substituents, phenyl group which may have substituents, naphthyl group which may have substituents, or 5- or 6-membered heterocycle which may have substituents and its condensed ring, ~~general~~ formula (3)




wherein Q2 denotes a C1~C4 alkylene, and R6 denotes a hydroxy group, lower alkoxy group which may be substituted with halogen atom, lower alkoxy carbonyl group, carboxy group, cycloalkyl group which may have substituents, cycloalkenyl group which may have substituents, phenyl group which may have substituents, naphthyl group which may have substituents, or 5- or 6-membered heterocycle which may have substituents and its condensed ring, or ~~general~~ formula (4)



wherein R7 and R8 denote identically or differently hydrogen atoms, lower alkyl groups which may be substituted with halogen atom, aralkyl groups which may have substituents, or R7 and R8 are bound together to form a 5- or 6- membered heterocycle which may have substituents and its condensed ring, or R3 and R4 are bound together to

form a 5- or 6-membered heterocycle which may have substituents and its condensed ring[[]],~~and their~~ or a pharmacologically acceptable addition [[salts]] salt thereof.


Claim 3 (Currently Amended): ~~4-Substituted~~ The 4-substituted aryl-5-hydroxyisoquinolinone ~~derivatives compound~~ of Claim 1, represented by a ~~general~~ formula (1b)



[[[]]]wherein ring Ar denotes a phenyl group, naphthyl group, 5- or 6-membered aromatic heterocycle [[and]] or its condensed ring, R1 denotes a hydrogen atom or halogen atom, R2a denotes a hydrogen atom, halogen atom, hydroxy group, lower alkyl group which may be substituted with halogen atom, lower alkoxy group which may be substituted with halogen atom, nitro group, or amino group which may have substituents, A1 denotes a C1~C4 alkylene, R3a denotes a hydrogen atom or lower alkyl group which may be substituted with halogen atom, R4a denotes a lower alkyl group which may be substituted with halogen atom, cycloalkyl group which may have substituents, ~~general~~ formula (3)




[[[]]]wherein Q2 denotes a C1~C4 alkylene, and R6 denotes a hydroxy group, lower alkoxy group which may be substituted with halogen atom, lower alkoxycarbonyl group, carboxy group, cycloalkyl group which may have substituents, cycloalkenyl group which may have substituents, phenyl group which may have substituents, naphthyl group which may have substituents, or 5- or 6-membered heterocycle which may have substituents and its condensed ring[[]], or ~~general~~ formula (4)



wherein R⁷ and R⁸ denote identically or differently hydrogen atoms, lower alkyl groups which may be substituted with halogen atom, aralkyl groups which may have substituents, or R⁷ and R⁸ are bound together to form a 5- or 6- membered heterocycle which may have substituents and its condensed ring, or R^{3a} and R^{4a} are bound together to form a 5- or 6-membered heterocycle which may have substituents and its condensed ring, and their or a pharmacologically acceptable addition salt thereof.

Claim 4 (Currently Amended): ~~4-Substituted~~ The 4-substituted aryl-5-hydroxyisoquinolinone ~~derivatives~~ compound of Claim 1, represented by a ~~general~~ formula (1c)




wherein ring Ar denotes a phenyl group, naphthyl group, 5- or 6-membered aromatic heterocycle or its condensed ring, R¹ denotes a hydrogen atom or halogen atom, R^{2a} denotes a hydrogen atom, halogen atom, hydroxy group, lower alkyl group which may be substituted with halogen atom, lower alkoxy group which may be substituted with halogen atom, nitro group, or amino group which may have substituents, A¹ denotes a C₁~C₄ alkylene, R^{3a} denotes a hydrogen atom or lower alkyl group which may be substituted with halogen atom, R^{4b} denotes a lower alkyl group which may be substituted with halogen atom, or general formula (3a)



[[([)]wherein Q2 denotes a C1~C4 alkylene, and R6a denotes a cycloalkyl group which may have substituents, cycloalkenyl group which may have substituents, phenyl group which may have substituents, naphthyl group which may have substituents, or 5- or 6-membered heterocycle which may have substituents and its condensed ring[[([)]], or R3a and R4b are bound together to form a 5- or 6-membered heterocycle which may have substituents and its condensed ring[[([)]],~~and their~~ or a pharmacologically acceptable addition [[salts]] salt thereof.

Claim 5 (Currently Amended): ~~4-Substituted~~ The 4-substituted aryl-5-hydroxyisoquinolinone ~~derivatives~~ compound of Claim 1, represented by a ~~general~~ formula (1d)




[[([)]wherein R1 denotes a hydrogen atom or halogen atom, R2a denotes a hydrogen atom, halogen atom, hydroxy group, lower alkyl group which may be substituted with halogen atom, lower alkoxy group which may be substituted with halogen atom, nitro group, or amino group which may have substituents, A1 denotes a C1~C4 alkylene, R3a denotes a hydrogen atom or lower alkyl group which may be substituted with halogen atom, R4b denotes a lower alkyl group which may be substituted with halogen atom, or ~~general~~ formula (3a)



[[([)]wherein Q2 denotes a C1~C4 alkylene, and R6a denotes a cycloalkyl group which may have substituents, cycloalkenyl group which may have substituents, phenyl group which may have substituents, naphthyl group which may have substituents, or 5- or 6-membered heterocycle which may have substituents and its condensed ring[[([)]], or R3a and R4b are bound together to form a 5- or 6-membered heterocycle which may have substituents


and its condensed ring[[]],~~and their~~ or a pharmacologically acceptable addition [[salts]] salt thereof.

Claim 6 (Currently Amended): ~~4-Substituted~~ The 4-substituted aryl-5-hydroxyisoquinolinone ~~derivatives compound~~ of Claim 1, represented by a ~~general~~ formula (1e)




[[]]wherein R1a denotes a hydrogen atom, R2b denotes a hydrogen atom, A1 denotes a C1~C4 alkylene, and R3b and R4c are bound together to form a 5- or 6-membered heterocycle which may have substituents and its condensed ring[[]],~~and their~~ or a pharmacologically acceptable addition [[salts]] salt thereof.

Claim 7 (Currently Amended): ~~4-Substituted~~ The 4-substituted aryl-5-hydroxyisoquinolinone ~~derivatives compound~~ of Claim 1, represented by a ~~general~~ formula (1f)



[[]]wherein R1a denotes a hydrogen atom, R2b denotes a hydrogen atom, A1 denotes a C1~C4 alkylene, R3c denotes a lower alkyl group which may be substituted with halogen atom, and R4d denotes a lower alkyl group which may be substituted with halogen atom[[]],~~and their~~ or a pharmacologically acceptable addition [[salts]] salt thereof.

Claim 8 (Currently Amended): ~~4-Substituted~~ The 4-substituted aryl-5-hydroxyisoquinolinone ~~derivatives~~ compound of Claim 1, represented by a ~~general~~ formula (1g)



[[[[]]]]wherein R1a denotes a hydrogen atom, R2b denotes a hydrogen atom, A1 denotes a C1~C4 alkylene, R3d denotes a hydrogen atom or lower alkyl group which may be substituted with halogen atom, R4e denotes ~~general~~ formula (3a)



[[[[]]]]wherein Q2 denotes a C1~C4 alkylene, and R6a denotes a cycloalkyl group which may have substituents, cycloalkenyl group which may have substituents, phenyl group which may have substituents, naphthyl group which may have substituents, or 5- or 6-membered heterocycle which may have substituents and its condensed ring[[[[]]]], ~~and their or~~ a pharmacologically acceptable addition [[salts]] salt thereof.

Claim 9 (Currently Amended): ~~Compounds~~ The compound of Claim 1, wherein the ~~compounds~~ compound represented by said ~~general~~ formula (1) ~~[[are]]~~ is selected from the group consisting of 1,2-dihydro-4-[4-(dimethylaminomethyl) phenyl]-5-hydroxy-1-oxoisoquinoline, 1,2-dihydro-5-hydroxy-4-[4-[(N-methylbenzylamino)methyl]phenyl]-1-oxoisoquinoline, 1,2-dihydro-5-hydroxy-4-[4-[(N-methyl-2-phenylethylamino) methyl] phenyl]-1-oxoisoquinoline, 1,2- dihydro-5-hydroxy-4 -[4-[(N-methyl-3-phenylpropylamino)methyl]phenyl]-1- oxoisoquinoline,1,2-dihydro-5-hydroxy-4-[4-[(N-methylcyclohexylmethylamino) methyl]phenyl]-1-oxoisoquinoline, 1,2-dihydro-5-hydroxy-1-oxo-4-[4-[(pyrrolidin-1-yl)methyl] phenyl]isoquinoline and 1,2-dihydro-5-hydroxy-1-oxo-4-[4- [(4-phenyl-1,2,3,6-tetrahydropyridin-1-yl)methyl]phenyl] isoquinoline.

Claim 10 (Currently Amended): An inhibitor of poly (ADP-ribose)synthetase, ~~characterized by containing one or more kinds of 4-substituted aryl-5-hydroxyisoquinolinone derivatives and their pharmacologically acceptable addition salts of any of claims 1 through 9 as effective ingredients comprising at least one compound according to claim 1.~~

Claims 11-16 (Canceled).

Claim 17 (New): A pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to claim 1 and at least one of a pharmacologically acceptable excipient or diluent.

Claim 18 (New): A method for inhibiting poly (ADP-ribose) synthetase, comprising administering a therapeutically effective amount of the compound of claim 1 to a human being or an animal.

Claim 19 (New): A method for treating ischemic diseases, comprising administering a therapeutically effective amount of the compound of claim 1 to a human being or an animal.

Claim 20 (New): The method according to claim 19, wherein the ischemic diseases are selected from the group consisting of cerebral infarction, cardiac infarction and acute renal failure.

Claim 21 (New): A method for treating inflammatory diseases, comprising administering a therapeutically effective amount of the compound of claim 1 to a human being or an animal.

Claim 22 (New): The method according to claim 21, wherein the inflammatory diseases are selected from the group consisting of inflammatory bowel disease, multiple cerebro sclerosis, arthritis and chronic rheumatism.

Claim 23 (New): A method for treating neurodegenerative diseases, comprising administering a therapeutically effective amount of the compound of claim 1 to a human being or an animal.

Claim 24 (New): The method according to claim 23, wherein the neurodegenerative diseases are selected from the group consisting of Alzheimer's disease, Huntington's chorea and Parkinson's disease.

Claim 25 (New): A method for treating diabetes and its complications, comprising administering a therapeutically effective amount of the compound of claim 1 to a human being or an animal.

Claim 26 (New): A method for treating brain trauma, comprising administering a therapeutically effective amount of the compound of claim 1.